HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.

AbstractINTRODUCTION:
Integration of targeted therapy and additional chemotherapy options has improved median overall survival (OS) in patients with unresectable metastatic colorectal cancer (mCRC). Cetuximab and panitumumab are examples of targeted therapies, specifically against the epidermal growth factor receptor (EGFR). This review focuses on Panitumumab, a fully human IgG2 monoclonal antibody, which inhibits key oncogenic downstream cell signalling pathways. Panitumumab and cetuximab have improved tumour response rate, progression-free survival, and OS in mCRC patients in whom the RAS (Rat Sarcoma) gene is of Wild Type (WT) status.
AREAS COVERED:
The EGFR signalling pathway and preclinical, Phase I and Phase II clinical studies on the pharmacokinetic, pharmacodynamic and safety evaluation of panitumumab are presented. Phase III studies utilising panitumumab in the first, second and third line setting in mCRC are also described.
EXPERT OPINION:
Panitumumab exhibits excellent pharmacokinetics and pharmacodynamics by way of uncomplicated dosing, non-existent drug interactions, minimal infusion reactions and manageable side effects, making it a suitable target for combination treatments. However, innate and acquired resistances are still obstacles. To overcome this, experimented strategies are ongoing, particularly in patients with Her-2 and BRAF gene alterations. Novel biomarkers to improve patient selection and second-generation targeted antibodies are in development.
AuthorsLouisa Lo, Dainik Patel, Amanda R Townsend, Timothy J Price
JournalExpert opinion on drug metabolism & toxicology (Expert Opin Drug Metab Toxicol) Vol. 11 Issue 12 Pg. 1907-24 ( 2015) ISSN: 1744-7607 [Electronic] England
PMID26572750 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Panitumumab
  • Cetuximab
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage, pharmacokinetics, pharmacology)
  • Antineoplastic Agents (administration & dosage, pharmacokinetics, pharmacology)
  • Cetuximab (administration & dosage, pharmacology)
  • Colorectal Neoplasms (drug therapy, genetics, pathology)
  • Disease-Free Survival
  • Humans
  • Molecular Targeted Therapy
  • Panitumumab
  • Patient Selection
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: